1-Bromo-5-(4-methylphenoxy)pentane | 53178-42-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-Bromo-5-(4-methylphenoxy)pentane
• 英文别名: 1-(5-Bromopentoxy)-4-methylbenzene
• CAS: 53178-42-0
• 化学式: C₁₂H₁₇BrO
• 分子量: 257.17
• InChiKey: LHYNMTUJSGGSRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-Bromo-5-(4-methylphenoxy)pentane 、 2,4-二(三甲硅氧基)嘧啶 以 neat (no solvent) 为溶剂， 反应 1.0h， 生成 1-[5-(4-methylphenoxy)pentyl]uracil
  参考文献：
  名称：

  Synthesis and anti-HCMV activity of 1-[ω-(phenoxy)alkyl]uracil derivatives and analogues thereof

  摘要：

  HCMV infection represents a life-threatening condition for immunocompromised patients and newborn infants and novel anti-HCMV agents are clearly needed. In this regard, a series of 1-[omega-(phenoxy)alkyl]uracil derivatives were synthesized and examined for antiviral properties. Compounds 17, 20, 24 and 28 were found to exhibit highly specific and promising inhibitory activity against HCMV replication in HEL cell cultures with EC50 values within 5.5-12 mu M range. Further studies should be undertaken to elucidate the mechanism of action of these compounds and the structure-activity relationship for the linker region. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.009
• 作为产物：
  描述：

  1-Bromo-5-(2-bromo-4-methylphenoxy)pentane 、 正丁基锂 以10%的产率得到
  参考文献：
  名称：

  BRADSHER C. K.; REAMES D. C., J. ORG. CHEM., 1981, 46, NO 7, 1384-1388

  摘要：

  DOI：

文献信息

• Synthesis of Potent Non-imidazole Histamine H3-Receptor Antagonists
  作者：C. Robin Ganellin、Fabien Leurquin、Antonia Piripitsi、Jean-Michel Arrang、Monique Garbarg、Xavier Ligneau、Walter Schunack、Jean-Charles Schwartz

  DOI：10.1002/(sici)1521-4184(199812)331:12<395::aid-ardp395>3.0.co;2-7

  日期：1998.12

  Histamine has been converted into a non‐imidazole H3‐receptor histamine antagonist by addition of a 4‐phenylbutyl group at the Nα‐position followed by removal of the imidazole ring. The resulting compound, N‐ethyl‐N‐(4‐phenylbutyl)amine, remarkably has a Ki = 1.3 μM as an H3 antagonist. Using this as a lead compound, a novel series of homologous O and S isosteric tertiary amines was synthesised and

  通过在 Nα-位添加 4-苯基丁基，然后去除咪唑环，组胺已转化为非-咪唑 H3-受体组胺拮抗剂。所得化合物 N-乙基-N-（4-苯基丁基）胺作为 H3 拮抗剂具有显着的 Ki = 1.3 μM。使用它作为先导化合物，合成了一系列新的同源 O 和 S 等排叔胺，结构-活性研究提供了 N-（5-苯氧基戊基）吡咯烷（Ki = 0.18 ± 0.10 μM，用于 [3H] 组胺从大鼠中释放大脑皮层突触体），更重要的是，它在体内是活跃的。将 NO2 取代到苯氧基的对位得到 N-(5-p-硝基苯氧基戊基)吡咯烷，UCL 1972 (Ki = 39 ± 11 nM)，ED50 = 1.1 ± 0.6 mg / kg per os in 脑远程小鼠甲基组胺水平。
• METHOD OF PRODUCING (METH)ACRYLOYL-TERMINATED POLYISOBUTYLENE POLYMER
  申请人：Kaneka Corporation

  公开号：EP3388454A1

  公开（公告）日：2018-10-17

  The object of the present invention is to provide a method for producing a (meth)acryloyl-terminated polyisobutylene polymer in which the auxiliary material used in the manufacture is easily removed, the burden of purification step and waste amount are decreased, and the transparency of the polymer is excellent. The method for producing the (meth)acryloyl-terminated polyisobutylene polymer contains a step 1 of polymerizing an isobutylene monomer under the presence of a Lewis acid catalyst to prepare a halogen-terminated polyisobutylene polymer (B), a step 2 of reacting the halogen-terminated polyisobutylene polymer (B) with a compound (C) having a halogen group and a phenoxy group under the presence a Lewis acid catalyst to prepare a halogenated phenoxyalkyl-terminated polyisobutylene polymer (D), and a step 3 of reacting the halogenated phenoxyalkyl-terminated polyisobutylene polymer (D) with an acrylic acid compound (E) to prepare the (meth)acryloyl-terminated polyisobutylene polymer (A).

  本发明的目的是提供一种生产(甲基)丙烯酰基封端的聚异丁烯聚合物的方法，该方法易于去除生产中使用的辅助材料，减少了纯化步骤的负担和废物量，并且聚合物的透明度极佳。(甲基)丙烯酰基封端聚异丁烯聚合物的生产方法包括步骤 1：在路易斯酸催化剂存在下聚合异丁烯单体，制备卤素封端聚异丁烯聚合物 (B)、步骤 2：在路易斯酸催化剂存在下，将卤素封端聚异丁烯聚合物（B）与具有卤素基和苯氧基的化合物（C）反应，制备卤代苯氧基烷基封端聚异丁烯聚合物（D），步骤 3：将卤代苯氧基烷基封端聚异丁烯聚合物（D）与丙烯酸化合物（E）反应，制备（甲基）丙烯酰基封端聚异丁烯聚合物（A）。
• Method of producing (meth)acryloyl-terminated polyisobutylene polymer
  申请人：Kaneka Corporation

  公开号：US10604598B2

  公开（公告）日：2020-03-31

  A method for producing a (meth)acryloyl-terminated polyisobutylene polymer includes a step 1 of polymerizing an isobutylene monomer under the presence of a Lewis acid catalyst to prepare a halogen-terminated polyisobutylene polymer (B), a step 2 of reacting the halogen-terminated polyisobutylene polymer (B) with a compound (C) having a halogen group and a phenoxy group under the presence a Lewis acid catalyst to prepare a halogenated phenoxyalkyl-terminated polyisobutylene polymer (D), and a step 3 of reacting the halogenated phenoxyalkyl-terminated polyisobutylene polymer (D) with an acrylic acid compound (E) to prepare the (meth)acryloyl-terminated polyisobutylene polymer (A).

  一种生产(甲基)丙烯酰基封端聚异丁烯聚合物的方法包括以下步骤 1 在路易斯酸催化剂存在下聚合异丁烯单体，制备卤素封端聚异丁烯聚合物 (B)、步骤 2：在路易斯酸催化剂存在下，将卤素封端聚异丁烯聚合物（B）与具有卤素基团和苯氧基基团的化合物（C）反应，制备卤代苯氧基烷基封端聚异丁烯聚合物（D），步骤 3：将卤代苯氧基烷基封端聚异丁烯聚合物（D）与丙烯酸化合物（E）反应，制备（甲基）丙烯酰基封端聚异丁烯聚合物（A）。
• EHDA, AKIXIDEH;XORI, MIKIO;YASUMOTO, SANDZI;YAMAVAKI, ITIRO;YAMADA, YUDZI+
  作者：EHDA, AKIXIDEH、XORI, MIKIO、YASUMOTO, SANDZI、YAMAVAKI, ITIRO、YAMADA, YUDZI+

  DOI：——

  日期：——
• Synthesis and anti-HCMV activity of 1-[ω-(phenoxy)alkyl]uracil derivatives and analogues thereof
  作者：Mikhail S. Novikov、Denis A. Babkov、Maria P. Paramonova、Anastasia L. Khandazhinskaya、Alexander A. Ozerov、Alexander O. Chizhov、Graciela Andrei、Robert Snoeck、Jan Balzarini、Katherine L. Seley-Radtke

  DOI：10.1016/j.bmc.2013.05.009

  日期：2013.7

  HCMV infection represents a life-threatening condition for immunocompromised patients and newborn infants and novel anti-HCMV agents are clearly needed. In this regard, a series of 1-[omega-(phenoxy)alkyl]uracil derivatives were synthesized and examined for antiviral properties. Compounds 17, 20, 24 and 28 were found to exhibit highly specific and promising inhibitory activity against HCMV replication in HEL cell cultures with EC50 values within 5.5-12 mu M range. Further studies should be undertaken to elucidate the mechanism of action of these compounds and the structure-activity relationship for the linker region. (C) 2013 Elsevier Ltd. All rights reserved.